Evaluating the role of quality assessment of primary studies in systematic reviews of cancer practice guidelines

BMC Medical Research Methodology

Volumn 5, Issue , 2005, Pages

  Brouwers, Melissa C ^a,b   Johnston, Mary E ^a,b   Charette, Manya L ^a,b   Hanna, Steve E ^a   Jadad, Alejandro R ^c   Browman, George P ^a,b,d  

^a MCMASTER UNIVERSITY   (Canada)

^b Program in Evidence based Care   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; BLOOD TRANSFUSION; CANCER MORTALITY; CANCER RESEARCH; CLINICAL PRACTICE; EVALUATION; OBSERVER VARIATION; PRACTICE GUIDELINE; PREDICTION; QUALITY CONTROL; RELIABILITY; REVIEW; VALIDATION PROCESS; CLINICAL TRIAL (TOPIC); CONFIDENCE INTERVAL; EVALUATION STUDY; HEALTH CARE QUALITY; HUMAN; LITERATURE; MORTALITY; NEEDS ASSESSMENT; NEOPLASMS; RISK; SENSITIVITY AND SPECIFICITY; UTILIZATION;

BLOOD TRANSFUSION; CLINICAL TRIALS AS TOPIC; CONFIDENCE INTERVALS; HUMANS; NEEDS ASSESSMENT; NEOPLASMS; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; QUALITY ASSURANCE, HEALTH CARE; REVIEW LITERATURE AS TOPIC; SENSITIVITY AND SPECIFICITY;

EID: 17844406885     PISSN: 14712288     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-5-8     Document Type: Review

References (34)

1. Lohr KN, Carey TS: Assessing "best evidence": issues in grading the quality of studies for systematic reviews. Jt Comm J Qual Improv 1999, 25:470-479.
2. Clarke M, Oxman AD, editors: Quality assessment of studies. Cochrane Reviewers Handbook 4.1.2 [updated March 2001]; Section 6. In The Cochrane Library Issue 2 Oxford: Update Software; 2001. Updated quarterly
3. Moher D, Cook DJ, Jadad AR, Tugwell P, Moher M, Jones A, Pham B, Klassen TP: Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess 1999, 3:1-98. i-iv
4. West S, King V, Carey TS, Lohr KN, McKoy N, Sutton SF, Lux L: Systems to Rate the Strength of Scientific Evidence. In Evidence Report/Technology Assessment No. 47 (Prepared by the Research Trial Institute - University of North Carolina Evidence-based Practice Center under Contrast No. 290-97-0011). AHRQ Publication No. 02-E016 Rockville, MD: Agency for Healthcare Research and Quality; 2002.
5. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998, 352:609-613.
6. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995, 273:408-412.
7. Colditz GA, Miller JN, Mosteller F: How study design affects outcomes in comparisons of therapy. Stat Med 1989, 8:441-466.
8. Ioannidis JP, Lau J: Can quality of clinical trials and meta-analyses be quantified? Lancet 1998, 352:590-591.
9. Greenland S: Quality scores are useless and potentially misleading. Am J Epidemiol 1994, 140:300-301.
10. Emerson JD, Burdick E, Hoaglin DC, Mosteller F, Chalmers TC: An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials. Control Clin Trials 1990, 11:339-352.
11. Verhagen AP, de Vet HC, Vermeer F, Widdershoven JWMG, de Bie RA, Kessels AGH, Boers M, van den Brandt PA: The influence of methodologic quality on the conclusion of a landmark metaanalysis on thrombolytic therapy. Int J Technol Assess Health Care 2002, 18(1):11-23.
12. Balk EM, Bonis PAL, Moskowitz H, Schmid CH, Ioannidis JPA, Wang C, Lau J: Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 2002, 287(22):2973-2982.
13. Verhagen AP, de Vet HC, de Bie RA, Lenssen AF, Kessels AG, Boers M, van den Brandt P: Impact of quality items on study outcome: treatments in acute lateral ankle sprains. Conference Proceedings of the First Symposium on Systematic Reviews: Beyond the Basics. Oxford; 1998. [abstract]
14. Juni P, Witschi A, Bloch R, Egger M: The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999, 282(11):1054-1060.
15. Browman GP, Levine MN, Mohide EA, Hayward RS, Pritchard KI, Gafni A, Laupacis A: The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995, 13:502-512.
16. Browman GP, Newman TE, Mohide EA, Graham I, Levine MN, Cowan DH: Progress of Clinical Oncology Guidelines Development Using the Practice Guidelines Development Cycle: The Role of Practitioner Feedback. J Clin Oncol 1998, 16(3):1226-1231.
17. Browman G, Brouwers M, De Vito C, Johnston M, Graham I: Participation Patterns of Oncologists in the Development of Clinical Practice Guidelines. Curr Oncol 2000, 7(4):252-257.
18. Pater JL, Browman GP, Brouwers MC, Nefsky MF, Evans WK, Cowan DH: Funding New Cancer Drugs in Ontario: Closing the loop in the Practice Guidelines Development Cycle. J Clin Oncol 2001, 19(14):3392-3396.
19. Browman GP: Development and aftercare of clinical guidelines: the balance between rigor and pragmatism. JAMA 2001, 286:1509-1511.
20. Moher D, Jadad AR, Tugwell P: Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 1996, 12:195-208.
21. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S: Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials 1995, 16:62-73.
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17:1-12.
23. Cho MK, Bero LA: Instruments for assessing the quality of drug studies published in the medical literature. JAMA 1994, 272:101-104.
24. Sindhu F, Carpenter L, Seers K: Development of a tool to rate the quality assessment of randomized controlled trials using a Delphi technique. J Adv Nurs 1997, 25:1262-1268.
25. Downs SH, Black N: The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998, 52:377-384.
26. McAlister FA, Clark HD, Wells PS, Laupacis A: Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg 1998, 85:171-178.
27. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD: Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997, 49:71-78.
28. Dube S, Heyen F, Jenicek M: Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 1997, 40:35-41.
29. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbe KA: Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992, 45:255-265.
30. Klein S, Simes J, Blackburn GL: Total parenteral nutrition and cancer clinical trials. Cancer 1986, 58:1378-1386.
31. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L: Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck 2001, 23:579-589.
32. Figueredo A, Germond C, Maroun J, Browman G, Walker-Dilks C, Wong S, the Gastrointestinal Cancer Disease Site Group: Adjuvant therapy for stage II colon cancer following complete resection. Cancer Prev Control 1997, 1:379-392.
33. Browman GP, Hodson DI, Newman T, the Head and Neck Cancer Disease Site Group: Neoadjuvant chemotherapy in locally advanced squamous cell carcinoma of the head and neck (excluding nasopharynx). Cancer Care Ontario Practice Guidelines Initiative Web site [http://hiru.mcmaster.ca/ccopgi/guidelines/head/ cpg5_1f.html]. 15 August 2001
34. Quirt I, Micucci S, Moran LA, Pater J, Browman G, the Systemic Treatment Disease Site Group : Erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. Cancer Prev Control 1997, 1:241-248.